

Royaume-Uni-Bristol: Services de pathologie

OJ S 21/2020 30/01/2020

Avis en cas de transparence ex ante volontaire

Services

Base juridique:

Directive 2014/24/UE

Section I: Pouvoir adjudicateur/entité adjudicatrice

I.1. Nom et adresses

Nom officiel: North Bristol NHS Trust

Adresse postale: Southmead Road, Bristol

Ville: Bristol

Code NUTS: UKK11 Bristol, City of

Code postal: BS10 5NB

Pays: Royaume-Uni

Point(s) de contact: Martin Strawson

Courriel: martin.strawson@UHBristol.nhs.uk

Téléphone: +44 1173420815

Adresse(s) internet:

Adresse principale: <https://www.nbt.nhs.uk/>

I.4. Type de pouvoir adjudicateur

Autre type: NHS trust

I.5. Activité principale

Santé

Section II: Objet

II.1. Étendue du marché

II.1.1. Intitulé

Procurement of a Large Throughput DNA Sequencer

Numéro de référence: BWPCCL001501

II.1.2. Code CPV principal

85111800 Services de pathologie

II.1.3. Type de marché

Services

II.1.4. Description succincte

The South West Genomic Hub Laboratory (SWGLH) based at North Bristol NHS Trust requires a large, high throughput DNA Sequencer for the processing new cancer panels at significant volume. The NovaSeq 6000 system provides the throughput, speed, and flexibility to complete next-generation sequencing (NGS) projects faster and more economically than ever before. A choice of 4 flow cell formats, multiple read length configurations, and the ability to run one or 2 flow cells simultaneously enable data output ranging from ~80 Gb-6000 Gb per run, providing flexibility across a broad range of applications and study sizes. The NovaSeq

6000 system combines unmatched system output with rapid run times to deliver the highest daily throughput of any NGS system currently available. With preconfigured reagent cartridges, RFID-encoded consumables, a choice between fully automated on board cluster generation and an individual lane loading workflow, the NovaSeq 6000 System provides simple, streamline.

II.1.6. Information sur les lots

Ce marché est divisé en lots: non

II.1.7. Valeur totale du marché

Valeur hors TVA: 779 625,00 GBP

II.2. Description

II.2.2. Code(s) CPV additionnel(s)

85111000 Services hospitaliers

II.2.3. Lieu d'exécution

Code NUTS: UKK11 Bristol, City of

II.2.4. Description des prestations

North Bristol NHS Trust is issuing this VEAT notice as the technical requirements of the high throughput next generation sequencing platform can only be met by one known supplier. North Bristol Trust is seeking a NGS sequencing system which will be able to process a high capacity of activity and to facilitate this intends to award a contract to Illumina Cambridge Ltd. NHS England has stated unequivocally that NHS cancer testing should move to a gene panel model. An investigation of the local testing portfolio suggests that > 70 % of the Trust's current range of tests could be condensed into a single gene panel. In this instance, the Trust would need the capacity to run in excess of 150 tests per week. The TTrust lacks the capacity to perform this volume of work on the current instruments, even if it did, the reagent costs would significantly exceed the costs of current testing.

To achieve the goal of efficient, cost effective workflows North Bristol Trust requires a very high capacity instrument to increase throughput, reduce turnaround times for reporting to molecular tumour boards, by purchasing a system that has a potential 1 day turnaround time (4 days for the full process DNA to data), generates up to 6 Tb of data (20 000 000 000 reads) per run and has cost effective reagent costs.

The NovaSeq would most likely be run in house using the S1 or S2 flowcells, with a capacity of 500 Gb or 1,25 Tb respectively. There are no other competing systems on the market with anything approaching this capacity. Switching to a 'universal' gene panel will allow an optimal workflow as all cancers will go on the same panel. This is likely to be around 500 genes. This is the only instrument on which the Trust could realistically run ctDNA sequencing for clinical purposes at sufficient depth to be clinically relevant.

Procurement to comprise:

Purchase of NovaSeq 6000 sequencing system with installation and training and 12 months warranty including parts and labour.

Purchase of Illumina Product Care NovaSeq 6000 comprehensive plan which includes full coverage for parts, labour and travel for 3 years contract.

II.2.5. Critères d'attribution

Critère de qualité - Nom: Quality / Pondération: 90

Prix - Pondération: 10

II.2.11.

Information sur les options

Options: non

II.2.13. Information sur les fonds de l'Union européenne

Le contrat s'inscrit dans un projet/programme financé par des fonds de l'Union européenne:
non

II.2.14. Informations complémentaires

Section IV: Procédure

IV.1. Description

IV.1.1. Type de procédure

Attribution d'un marché sans publication préalable d'un avis d'appel à la concurrence au Journal officiel de l'Union européenne (dans les cas énumérés ci-dessous)

- Le contrat ne relève pas du champ d'application de la directive

Explication:

North Bristol NHS Trust is issuing this VEAT notice as the technical requirements of the high throughput next generation sequencing platform can only be met by one known supplier. North Bristol Trust is seeking a NGS sequencing system which will be able to process a high capacity of activity and to facilitate this intends to award a contract to Illumina Cambridge Ltd. NHS England has stated unequivocally that NHS cancer testing should move to a gene panel model. An investigation of the local testing portfolio suggests that > 70 % of the Trust's current range of tests could be condensed into a single gene panel. In this instance, the Trust would need the capacity to run in excess of 150 tests per week. The TTrust lacks the capacity to perform this volume of work on the current instruments, even if it did, the reagent costs would significantly exceed the costs of current testing.

To achieve the goal of efficient, cost effective workflows North Bristol Trust requires a very high capacity instrument to increase throughput, reduce turnaround times for reporting to molecular tumour boards, by purchasing a system that has a potential 1 day turnaround time (4 days for the full process DNA to data), generates up to 6 Tb of data (20 000 000 000 reads) per run and has cost effective reagent costs.

The NovaSeq would most likely be run in house using the S1 or S2 flowcells, with a capacity of 500 Gb or 1,25 Tb respectively. There are no other competing systems on the market with anything approaching this capacity. Switching to a 'universal' gene panel will allow an optimal workflow as all cancers will go on the same panel. This is likely to be around 500 genes. This is the only instrument on which the Trust could realistically run ctDNA sequencing for clinical purposes at sufficient depth to be clinically relevant.

Procurement to comprise:

Purchase of NovaSeq 6000 sequencing system with installation and training and 12 months warranty including parts and labour.

Purchase of Illumina Product Care NovaSeq 6000 comprehensive plan which includes full coverage for parts, labour and travel for 3 years contract.

IV.1.3. Information sur l'accord-cadre

IV.1.8. Information concernant l'accord sur les marchés publics (AMP)

Le marché est couvert par l'accord sur les marchés publics: non

IV.2. Renseignements d'ordre administratif

Section V: Attribution du marché/de la concession

Intitulé:

Procurement of Large High Throughput DNA Sequencer

V.2. Attribution du marché/de la concession

V.2.1. Date d'attribution du marché

28/01/2020

V.2.2. Informations sur les offres

Le marché a été attribué à un groupement d'opérateurs économiques: non

V.2.3. Nom et adresse du titulaire/concessionnaire

Nom officiel: Illumina Cambridge Ltd

Adresse postale: Chesterford Research Park, Little Chesterford

Ville: Saffron Walden

Code NUTS: UKI London

Code postal: CB10 1XL

Pays: Royaume-Uni

Le titulaire/concessionnaire sera une PME: oui

V.2.4. Informations sur le montant du marché/du lot/de la concession

Valeur totale du marché/du lot/de la concession: 779 625,00 GBP

V.2.5. Information sur la sous-traitance

Section VI: Renseignements complémentaires

VI.3. Informations complémentaires

VI.4. Procédures de recours

VI.4.1. Instance chargée des procédures de recours

Nom officiel: Bristol and Weston Purchasing Consortium

Adresse postale: Level 3, Whitefriars, Lewins Mead

Ville: Bristol

Code postal: BS1 2NT

Pays: Royaume-Uni

Courriel: martin.strawson@UHBristol.nhs.uk

VI.4.2. Organe chargé des procédures de médiation

Nom officiel: Bristol and Weston Purchasing Consortium

Adresse postale: Level 3, Whitefriars, Lewins Mead

Ville: Bristol

Code postal: BS1 2NT

Pays: Royaume-Uni

VI.4.4. Service auprès duquel des renseignements peuvent être obtenus sur l'introduction de recours

Nom officiel: Bristol and Weston Purchasing Consortium

Adresse postale: Level 3, Whitefriars, Lewins Mead

Ville: Bristol

Code postal: BS1 2NT

Pays: Royaume-Uni

VI.5. Date d'envoi du présent avis

28/01/2020